Fierce Biotech: Chutes & Ladders

Elicio Therapeutics, developing immunotherapies that leverage its proprietary lymph node targeting technology, has named Annette Matthies, Ph.D., as chief business officer. Matthies played a key role in the initial public offering for Receptos, later picked up by Celgene for $7.2 billion, and also worked at Abbott Laboratories after its $450 million buyout of Facet Biotech, where she served in a post-acquisition integration position. FULL STORY